SBIO's Novel JAK2 Inhibitor SB1518 Is Shown To Be A Safe And Effective Therapy In Phase 1/2 Studies For Patients With Symptomatic Myelofibrosis
Links shared publicly online about this topic.
- 672total visits
SBIO's Novel JAK2 Inhibitor SB1518 Is Shown To Be A Safe And Effective Therapy In Phase 1/2 Studies For Patients With Symptomatic Myelofibrosis
SBIO Pte Ltd announced that data from Phase 1/2 studies for its novel JAK2 inhibitor SB1518 indicates clinical efficacy and good tolerability for the treatment of patients with symptomatic myelofi
View full resource at medicalnewstoday.com
Tags: Safety
Most Recently Shared on December 8, 2010 at 12:05 am By:
SBIO's Novel JAK2 Inhibitor SB1518 Is Shown To Be A Safe And Effective Therapy In Phase 1/2 Studies For Patients With ... http://mnt.to/3NFY
Also Shared By:
Advertisement
MNT Leukemia
@mnt_leukemia
SBIO's Novel JAK2 Inhibitor SB1518 Is Shown To Be A Safe And Effective Therapy In Phase 1/2 Studies For Patients With ... http://mnt.to/3NFY
1 year ago...